Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

278 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Poor survival for veterans with pathologic stage I non-small-cell lung cancer.
St Julien JB, Pinkerman R, Aldrich MC, Chen H, Deppen SA, Callaway-Lane C, Massion P, Putnam JB, Lambright ES, Nesbitt JC, Grogan EL. St Julien JB, et al. Among authors: massion p. Am J Surg. 2012 Nov;204(5):637-42. doi: 10.1016/j.amjsurg.2012.07.008. Epub 2012 Aug 18. Am J Surg. 2012. PMID: 22906246 Free PMC article.
Proteomic patterns of tumour subsets in non-small-cell lung cancer.
Yanagisawa K, Shyr Y, Xu BJ, Massion PP, Larsen PH, White BC, Roberts JR, Edgerton M, Gonzalez A, Nadaf S, Moore JH, Caprioli RM, Carbone DP. Yanagisawa K, et al. Among authors: massion pp. Lancet. 2003 Aug 9;362(9382):433-9. doi: 10.1016/S0140-6736(03)14068-8. Lancet. 2003. PMID: 12927430
Nuclear survivin as a biomarker for non-small-cell lung cancer.
Lu B, Gonzalez A, Massion PP, Shyr Y, Shaktour B, Carbone DP, Hallahan DE. Lu B, et al. Among authors: massion pp. Br J Cancer. 2004 Aug 2;91(3):537-40. doi: 10.1038/sj.bjc.6602027. Br J Cancer. 2004. PMID: 15266313 Free PMC article.
Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.
Taguchi F, Solomon B, Gregorc V, Roder H, Gray R, Kasahara K, Nishio M, Brahmer J, Spreafico A, Ludovini V, Massion PP, Dziadziuszko R, Schiller J, Grigorieva J, Tsypin M, Hunsucker SW, Caprioli R, Duncan MW, Hirsch FR, Bunn PA Jr, Carbone DP. Taguchi F, et al. Among authors: massion pp. J Natl Cancer Inst. 2007 Jun 6;99(11):838-46. doi: 10.1093/jnci/djk195. J Natl Cancer Inst. 2007. PMID: 17551144
Smoking-related genomic signatures in non-small cell lung cancer.
Massion PP, Zou Y, Chen H, Jiang A, Coulson P, Amos CI, Wu X, Wistuba I, Wei Q, Shyr Y, Spitz MR. Massion PP, et al. Am J Respir Crit Care Med. 2008 Dec 1;178(11):1164-72. doi: 10.1164/rccm.200801-142OC. Epub 2008 Sep 5. Am J Respir Crit Care Med. 2008. PMID: 18776155 Free PMC article.
Mass spectrometry-based proteomic profiling of lung cancer.
Ocak S, Chaurand P, Massion PP. Ocak S, et al. Among authors: massion pp. Proc Am Thorac Soc. 2009 Apr 15;6(2):159-70. doi: 10.1513/pats.200809-108LC. Proc Am Thorac Soc. 2009. PMID: 19349484 Free PMC article. Review.
Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen.
Salmon S, Chen H, Chen S, Herbst R, Tsao A, Tran H, Sandler A, Billheimer D, Shyr Y, Lee JW, Massion P, Brahmer J, Schiller J, Carbone D, Dang TP. Salmon S, et al. Among authors: massion p. J Thorac Oncol. 2009 Jun;4(6):689-96. doi: 10.1097/JTO.0b013e3181a526b3. J Thorac Oncol. 2009. PMID: 19404214 Free PMC article. Clinical Trial.
278 results